A counterfeit version of BiCNU has been detected in foreign countries, the Food and Drug Administration reports.

BiCNU is approved to treat different types of brain cancer, multiple myeloma, and lymphoma (Hodgkin’s and non-Hodgkin’s), manufactured by Emcure Pharmaceuticals, and distributed by Heritage Pharmaceuticals.

There has been no counterfeit BiCNU detected in the United States, but the FDA encourages health care professionals to diligently inspect BiCNU vials before administering the drug to patients.

“While the [National Drug Code] on the outer package of the authentic and counterfeit version might match, the best way to distinguish a counterfeit is to look at the BiCNU vial inside the packaging,” the FDA reported in a written statement , which includes a list of the counterfeit lots.

To report sales solicitation of suspect drugs call the FDA’s office of criminal investigations at 800-551-3989 or e-mail DrugSupplyChainIntegrity@fda.hhs.gov. To report adverse events related to suspect medications, submit a report online at www.fda.gov/medwatch/report.htm .


On Twitter @jess_craig94


You May Also Like

Safety of bioresorbable stents does not match that of metal stents

AT CARDIOVASCULAR RESEARCH TECHNOLOGIES 2016 Bioresorbable vascular scaffold stents are improving rapidly but they ...

Endocrinologists report little training in transgender care

FROM THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Although endocrinologists are often the go-to ...

Cabozantinib versus everolimus in advanced RCC with bone mets

AT ECCO2017 AMSTERDAM (FRONTLINE MEDICAL NEWS) – Among patients with advanced renal cell carcinoma ...